Eventide Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-4,160,608
| Closed | -$20.1M | – | 146 |
|
|
2020
Q1 | $20.1M | Hold |
4,160,608
| – | – | 0.65% | 60 |
|
|
2019
Q4 | $44.2M | Hold |
4,160,608
| – | – | 1.25% | 32 |
|
|
2019
Q3 | $43.3M | Buy |
4,160,608
+967,881
| +30% | +$12.7M | 1.43% | 26 |
|
|
2019
Q2 | $48.9M | Buy |
3,192,727
+1,583,204
| +98% | +$22.9M | 1.49% | 20 |
|
|
2019
Q1 | $20.7M | Buy |
1,609,523
+523,123
| +48% | +$5.91M | 0.71% | 53 |
|
|
2018
Q4 | $10.3M | Hold |
1,086,400
| – | – | 0.46% | 68 |
|
|
2018
Q3 | $18M | Hold |
1,086,400
| – | – | 0.66% | 55 |
|
|
2018
Q2 | $17.4M | Hold |
1,086,400
| – | – | 0.72% | 52 |
|
|
2018
Q1 | $16.6M | Hold |
1,086,400
| – | – | 0.78% | 50 |
|
|
2017
Q4 | $16.9M | Hold |
1,086,400
| – | – | 0.88% | 42 |
|
|
2017
Q3 | $12.1M | Hold |
1,086,400
| – | – | 0.68% | 54 |
|
|
2017
Q2 | $9.99M | Hold |
1,086,400
| – | – | 0.62% | 50 |
|
|
2017
Q1 | $9.29M | Buy |
1,086,400
+235,000
| +28% | +$2.14M | 0.62% | 52 |
|
|
2016
Q4 | $9.11M | Hold |
851,400
| – | – | 0.59% | 52 |
|
|
2016
Q3 | $9.22M | Hold |
851,400
| – | – | 0.56% | 50 |
|
|
2016
Q2 | $5.76M | Hold |
851,400
| – | – | 0.35% | 69 |
|
|
2016
Q1 | $3.97M | Hold |
851,400
| – | – | 0.22% | 82 |
|
|
2015
Q4 | $5.37M | Buy |
851,400
+116,400
| +16% | +$945K | 0.27% | 85 |
|
|
2015
Q3 | $6.49M | Buy |
735,000
+30,750
| +4% | +$323K | 0.38% | 65 |
|
|
2015
Q2 | $8.29M | Buy |
704,250
+84,050
| +14% | +$1.17M | 0.45% | 60 |
|
|
2015
Q1 | $8.97M | Buy |
620,200
+19,700
| +3% | +$302K | 0.68% | 55 |
|
|
2014
Q4 | $10.2M | Buy |
600,500
+20,700
| +4% | +$299K | 1.12% | 38 |
|
|
2014
Q3 | $7.22M | Buy |
579,800
+20,000
| +4% | +$246K | 1.01% | 42 |
|
|
2014
Q2 | $8.21M | Buy |
559,800
+197,400
| +54% | +$3.03M | 1.12% | 43 |
|
|
2014
Q1 | $7.38M | Buy |
362,400
+154,300
| +74% | +$3.74M | 1.15% | 43 |
|
|
2013
Q4 | $4.08M | Buy |
+208,100
| New | +$5.55M | 1.26% | 42 |
|
Eventide Asset Management's STML Position: Q2 2020 in Review
Eventide Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 4,160,608 shares — an estimated $20.1M sold.
Eventide Asset Management first reported a position in STML in Q4 2013 and held it in 26 quarters. The position peaked at $48.9M in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Eventide Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Eventide Asset Management sold 4,160,608 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $20.1M.
- Eventide Asset Management first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 26 quarters.
- Eventide Asset Management's Stemline Therapeutics, Inc. position peaked at $48.9M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Eventide Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.